Bracco Imaging launches BubbleGen CD3+ kit
Analysis based on 6 articles · First reported Sep 09, 2026 · Last updated Sep 09, 2026
The launch of the BubbleGen CD3+ T Cell Selection Kit could strengthen Bracco S.p.A. — Bracco Imaging's position in the cell therapy manufacturing market by offering a novel bead-free alternative. This may positively impact Bracco's revenue prospects in the growing cell therapy sector, though the immediate market impact is limited as the product is for research use only.
Bracco S.p.A. — Bracco Imaging, a global pharmaceutical company, announced the expansion of its BubbleGen cell selection portfolio with the launch of the BubbleGen CD3+ T Cell Selection Kit. The kit, built on Bracco's microbubble technology, enables magnetic bead-free cell selection for cell therapy research and development, including a scalable and cost-effective approach to manufacturing CAR-T cell therapies. This is the first of multiple planned expansions following the launch of an early access program in May 2026. The technology uses antibody-targeted lipid microbubbles that selectively bind desired cell populations and then dissipate, eliminating magnetic iron residuals and column-related cell loss. The kit is designed for CD3+ T-cell isolation and supports applications such as T cell isolation, depletion, CAR-T and TCR-T development, and process development workflows. It is compatible with automated and closed manufacturing systems and is expected to be available for clinical use in 2027. The kit is now available for research use, and Bracco will introduce it at the CAR-TCR Summit in Boston on September 16-17, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard